Cargando…
COVID-19: Older drugs for a novel disease—Chloroquine, hydroxychloroquine, and possible Pentoxifylline—set to start the second innings?
Currently no drug is approved for the prophylaxis and management of COVID 19. Lots of activities on vaccine and trials with drugs are underway. Some evidence have shown positive results using older established drug in the management of severe cases. We are also of same view and opinion to adopt some...
Autores principales: | Thangaraju, Pugazhenthan, Gurunthalingam, Meenalotchini P., Varthya, Shobanbabu, Venkatesan, Sajitha, Thangaraju, Eswaran |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer - Medknow
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7380773/ https://www.ncbi.nlm.nih.gov/pubmed/32754467 http://dx.doi.org/10.4103/jfmpc.jfmpc_422_20 |
Ejemplares similares
-
COVID-19: Wait for a novel drug or act with the age old drug – Do we have a choice?
por: Thangaraju, Pugazhenthan, et al.
Publicado: (2020) -
Can HCQ Be Considered a “Safe Weapon” for COVID-19 in the Indian Population?
por: Thangaraju, Pugazhenthan, et al.
Publicado: (2020) -
Chloroquine induced utricaria—A detailed history helps
por: Thangaraju, Pugazhenthan, et al.
Publicado: (2019) -
Rationale use of Thalidomide in erythema nodosum leprosum - A non-systematic critical analysis of published case reports
por: Thangaraju, Pugazhenthan, et al.
Publicado: (2020) -
Cephalosporin's induced hepatic enzyme derangement - An educational report
por: Thangaraju, Pugazhenthan, et al.
Publicado: (2020)